Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: Implication of a CYP3A4 activity profile

International Journal of Clinical and Experimental Medicine

Volumn 6, Issue 7, 2013, Pages 552-561

  Assis, Joana ^a,d   Pereira, Deolinda ^a,b   Gomes, Mónica ^a,b,d   Marques, Dânia ^a   Marques, Inês ^a   Nogueira, Augusto ^a,d   Catarino, Raquel ^a   Medeiros, Rui ^a,b,c,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c CEBIMED   (Portugal)

^d Portuguese League Against Cancer (Norte)   (Portugal)

Author keywords

Cyp3a4; Paclitaxel; Pharmacogenetic; Polymorphism; Predictive value; Serous ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOCHROME P450 3A4; PACLITAXEL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CYP3A4 GENE; CYTOREDUCTIVE SURGERY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; SEROUS OVARIAN CANCER; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84881039079     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Ferlay J, Parkin DM and Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
4. Medel NIB, Wright JD and Herzog TJ. Targeted therapies in epithelial ovarian cancer. J Oncol 2010; 314-326.
5. Bhoola S and Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006; 107: 1399-1410.
6. Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 2003; 21: 149-167.
7. Pinto D, Pereira D, Portela C, Da Silva JL, Lopes C and Medeiros R. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 2005; 335: 1173-1178.
8. Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, Freitas-Silva M, Vasconcelos A, Costa S, Osorio T and Lopes C. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione Stransferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 2003; 8: 156-161.
9. Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R, Rodrigues C, Araujo AP, Lopes C and Medeiros R. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxelbased chemotherapy in ovarian cancer. Biochem Biophys Res Commun 2006; 340: 256-262.
10. Bergmann TK, Green H, Brasch-Andersen C, Mirza MR, Herrstedt J, Holund B, Du Bois A, Damkier P, Vach W, Brosen K and Peterson C. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011; 67: 693-700.
11. Gajjar K, Owens G, Sperrin M, Martin-Hirsch PL and Martin FL. Cytochrome P1B1 gene (CYP1B1) polymorphisms and ovarian cancer risk: A meta-analysis. Toxicology 2012; 302: 157-162.
12. Peethambaram P, Fridley BL, Vierkant RA, Larson MC, Kalli KR, Elliott EA, Oberg AL, White KL, Rider DN, Keeney GL, Cunningham JM, Hartmann LC and Goode EL. Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. Int J Mol Epidemiol Genet 2011; 2: 185-195.
13. Bozina N, Bradamante V and Lovric M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 2009; 60: 217-242.
14. Burk O and Wojnowski L. Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 105-124.
15. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
16. Rodriguez-Antona C and Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006; 25: 1679-1691.
17. van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005; 23: 513-522.
18. Chu W, Fyles A, Sellers EM, McCready DR, Murphy J, Pal T and Narod SA. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis 2007; 28: 2139-2142.
19. Westlind A, Lofberg L, Tindberg N, Andersson TB and Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem Biophys Res Commun 1999; 259: 201-205.
20. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR and Ingelman-Sundberg M. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003; 31: 755-761.
21. Lamba JK, Lin YS, Schuetz EG and Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-1294.
22. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ and Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-1229.
23. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF and Rebbeck TR. Increased transcrip tional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003; 42: 299-305.
24. Nogal A, Coelho A, Catarino R, Morais A, Lobo F and Medeiros R. The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population. Cancer Genet Cytogenet 2007; 177: 149-152.
25. Zhang W, Chang YZ, Kan QC, Zhang LR, Li ZS, Lu H, Wang ZY, Chu QJ and Zhang J. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol 2010; 66: 61-66.
26. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA and Rebbeck TR. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998; 95: 13176-13181.
27. Rodrigues IS, Kuasne H, Losi-Guembarovski R, Fuganti PE, Gregorio EP, Kishima MO, Ito K, de Freitas Rodrigues MA and de Syllos Colus IM. Evaluation of the influence of polymorphic variants CYP1A1*2B, CYP1B1*2, CYP3A4*1B, GSTM1*0, and GSTT1*0 in prostate cancer. Urol Oncol 2010; 29: 654-663.
28. Becker ML, Visser LE, Van Schaik RH, Hofman A, Uitterlinden AG and Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf 2010; 19: 75-81.
29. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, McCredie MR, Giles GG, Chenevix-Trench G and Liddle C. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002; 12: 355-366.
30. Wandel C, Witte JS, Hall J., Stein CM, Wood AJ and Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther 2000; 68: 82-91.
31. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N and Hall J. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66: 288-294.
32. He BX, Shi L, Qiu J, Tao L, Li R, Yang L and Zhao SJ. A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. Basic Clin Pharmacol Toxicol 2011; 108: 208-213.
33. Wang D, Guo Y, Wrighton SA, Cooke GE and Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011; 11: 274-286.
34. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, McBride S, Deitz A, Malkowicz SB, Ofori-Adjei D, Gueye SM and Rebbeck TR. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002; 54: 13-21.
35. Kadlubar FF, Berkowitz GS, Delongchamp RR, Wang C, Green BL, Tang G, Lamba J, Schuetz E and Wolff MS. The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 327-331.
36. Anglicheau D, Le Corre D, Lechaton S, LaurentPuig P, Kreis H, Beaune P, Legendre C and Thervet E. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5: 595-603.
37. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W and van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.
38. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T and van Schaik RH. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 1574-1583.
39. Farley J, Ozbun LL and Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res 2008; 18: 538-548.
40. Bast RCJ, Hennessy B and Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415-428.
41. Medeiros R, Soares R, Vasconcelos A, Schmitt F and Lopes C. Glutathione S-transferase genotype GSTM1 as a predictor of elevated angiogenic phenotype in patients with early onset breast cancer. Angiogenesis 2004; 7: 53-58.
42. Nogueira A, Catarino R, Faustino I, NogueiraSilva C, Figueiredo T, Lombo L, Hilario-Silva I, Pereira D and Medeiros R. Role of the RAD51 G172T polymorphism in the clinical outcome of cervical cancer patients under concomitant chemoradiotherapy. Gene 2012; 504: 279-283.
43. Silva J, Teixeira AL, Lobo F, Mauricio J and Medeiros R. DNA Repair System and Prostate Cancer Progression: The Role of NBS1 Poly-morphism (rs1805794). DNA Cell Biol 2012; 31: 1182-6.
44. Catarino R, Araujo A, Coelho A, Gomes M, Nogueira A, Lopes C and Medeiros RM. Prognostic significance of telomerase polymorphism in non-small cell lung cancer. Clin Cancer Res 2010; 16: 3706-3712.
45. Clarke SJ and Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99-114.
46. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM and Altman RB. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 2001; 1: 167-170.
47. Harris JW, Rahman A, Kim BR, Guengerich FP and Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994; 54: 4026-4035.
48. Kim H, Kang HJ, Kim HJ, Jang MK, Kim NH, Oh Y, Han BD, Choi JY, Kim CW, Lee JW, Park KD, Shin HY and Ahn HS. Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism. PLoS One 2012; 7: e45558.
49. Walko CM, Combest AJ, Spasojevic I, Yu AY, Bhushan S, Hull JH, Hoskins J, Armstrong D, Carey L, Collicio F and Dees EC. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 2012; 69: 1189-1196.
50. Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR and DeMichele A. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 2010; 12: 26.
51. Ociepa-Zawal M, Rubis B, Filas V, Breborowicz J and Trzeciak WH. Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients. Ginekol Pol 2009; 80: 819-823.
52. Kurman RJ and Shih IEM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008; 27: 151-160.
53. Downie D, McFadyen MC, Rooney PH, Cruickshank ME, Parkin DE, Miller ID, Telfer C, Melvin WT and Murray GI. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 2005; 11: 7369-7375.
54. Cadron I, Abdulkadir L, Despierre E, Berteloot P, Neven P, Leunen K, Amant F and Vergote I. The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. Gynecol Oncol 2013; 128: 34-37.
55. Wu CH, Yang CH, Lee JN, Hsu SC and Tsai EM. Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects. Int J Gynecol Cancer 2001; 11: 295-299.
56. Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, Clarke-Pearson DL, Rodriguez GC and Carney ME. Weekly lowdose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 2003; 88: 51-57.
57. Watanabe Y, Nakai H, Ueda H and Hoshiai H. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer. Gynecol Oncol 2005; 96: 323-329.
58. Sharma R, Graham J, Mitchell H, Brooks A, Blagden S and Gabra H. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009; 100: 707-712.
59. Leiser AL, Maluf FC, Chi DS, Sabbatini P, Hensley ML, Schwartz L, Venkatraman E, Spriggs D and Aghajanian C. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. Int J Gynecol Cancer 2007; 17: 379-386.
60. Taniguchi R, Kumai T, Matsumoto N, Watanabe M, Kamio K, Suzuki S and Kobayashi S. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci 2005; 97: 83-90.
61. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, Sparreboom A and McLeod HL. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005; 11: 8097-8104.
62. Fransson MN, Green H, Litton JE and Friberg LE. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab Dispos 2011; 39: 247-255.